Navigation Links
Pharmasset Reports Fiscal Year End 2011 Financial Results
Date:11/14/2011

eks of PSI-7977 400 mg QD with PEG/RBV, 43/44, or 98% (91% ITT), achieved SVR12, confirming selection of the PSI-7977 400 mg QD dose for Phase3 studies.  

At the company's investor event on November 6th, interim data from the open-label ATOMIC trial provided preliminary confirmation of the 12-week duration of PSI-7977 for all HCV genotypes, with an initial 15 of 15 subjects with HCV GT1 remaining HCV RNA "undetectable" at the SVR4 timepoint.  Interferon-free assessments of PSI-7977/RBV in HCV GT1 are ongoing in ELECTRON and QUANTUM.  

Collaborative Trials with PSI-7977In the third calendar quarter, Bristol-Myers Squibb completed enrollment of a collaborative trial of 24 weeks of PSI-7977 with the BMS NS5a inhibitor, daclatasvir (with and without ribavirin) in patients with HCV GT1, GT2 or GT3. Recently, Bristol-Myers Squibb announced that four 12-week cohorts of the combination had been added in patients with HCV GT1 who: 1) are naive to prior therapy, or 2) had previously failed an HCV protease inhibitor with Peg-IFN/RBV.

In the fourth calendar quarter of 2011, Tibotec started screening patients in a collaborative study of their HCV protease inhibitor, TMC435, in combination with PSI-7977, in patients with HCV GT1 with a prior "null" response to prior Peg-IFN/RBV therapy.  All subjects will be treated for 12 or 24 weeks, and will be randomized to therapies with or without ribavirin.

A collaborative study with the National Institutes of Health initiated in the third calendar quarter of 2011, evaluating 24 weeks of PSI-7977 with or without ribavirin in patients with HCV GT1

PSI-938In September 2011, QUANTUM was initiated, a phase 2b study of Pharmasset's purine, PSI-938, administered as monotherapy and in combination with PSI-7977 (with and without ribavirin). Two treatment arms of PSI-7977 and RBV without PSI-938 are also included. All combinations will be evaluated for 12 and 24 weeks. 
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
5. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
10. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
11. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company" ... pleased to announce that the Company will be presenting ... to be held in London, UK ... Mr. James Mellon , a director of Portage, ... key programs at its subsidiaries, Portage Pharmaceuticals Ltd. ("PPL"), ...
(Date:4/16/2015)... ON , April 16, 2015 /CNW/ - Bioenterprise Corporation ... its newest office in Charlottetown , ... the Prince Edward Island ADAPT Council for the commercialization ... looking forward to working with PEI ADAPT.  They have ... for more than a decade," explains Dave Smardon ...
(Date:4/16/2015)... AZ (PRWEB) April 16, 2015 A ... makes it easier for research institutions to learn how ... clinical data. , The timing is ideal since Apple ... Tuesday. Research Kit is an open-source framework for developing ... It provides a way for researchers to collect secure ...
(Date:4/16/2015)... BURLINGAME, Calif. , April 16, 2015  Scientists ... session, "New Drugs on the Horizon," at the American ... Philadelphia, PA on Sunday, April 19, ... , Ph.D., Cleave,s Director of Biology, will present new ... CB-5083, a first-in-class, oral inhibitor of p97, a critical ...
Breaking Biology Technology:Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Bioenterprise Corporation Expands into the Maritimes 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... NEW YORK, Oct. 10, 2011 In response to Rubicon,s ... E. Sandell sent today the following letter to Rubicon,s Board ... 3 7 - 9 Fanshawe Street Auckland New Zealand Attn: ... Dear Gentlemen: As you are aware, funds ...
... Iceland, October 9, 2011 Scientists at deCODE ... and the USA today report the discovery of low frequency ... gout, a common inflammatory arthritis, and serum uric acid levels. ... is published today in the online edition of Nature ...
... In support of Breast Cancer Awareness LensWay.co.uk will ... There are over 50 styles to choose from and starting ... range of pink glasses please visit the following page: ... For women in the UK breast cancer is the most ...
Cached Biology Technology:Sandell Asset Management Seeks Sale of Rubicon & Tenon, Expansion of Board 2Sandell Asset Management Seeks Sale of Rubicon & Tenon, Expansion of Board 3deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels 2deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels 3Buy Pink Glasses From LensWay and £20 Will be Donated to Breast Cancer Research 2
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/23/2015)... SoundView Technology Group issues a new research update ... Wocket smart wallet. SoundView was one of the selected user groups ... the Wocket in multiple scenarios and outlets. ... retailers, making both debit and credit card payments.  ... the company meets their plans in 2015, it would push ...
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... the nutrient-poor soils in which they grow by trapping ... of the genus Nepenthes were thought to capture their ... paper in this weeks PLoS ONE, Laurence Gaume and ... CNRS, working respectively in the University of Montpellier and ...
... A joint Yale-Peking University center that aims to ... will receive five years of continued and expanded support ... technology. The company will fund student exchanges and ... Peking-Yale Joint Center (PYC) for Plant Molecular Genetics and ...
... CO 2 emissions from using coal are set to double ... of mitigating global climate change. In view of the essential ... minimise emissions where coal is used. The British ... Coal (NZEC) Phase 1 study in Beijing, China today. The aim ...
Cached Biology News:Carnivorous plants use pitchers of 'slimy saliva' to catch their prey 2Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center 2UK scientists lead China closer to carbon capture and storage 2
... Gene Pulser Xcell microbial system, 100 ... used for electroporation of bacterial and ... main unit, PC module for exponential ... sterile cuvettes (5 each of 0.1 ...
... Array (MSTA) slides were designed to study protein ... multiple species. Tissue slices from three different ... can then be treated as a single histological ... situ hybridization. This format allows a ...
... is used to predict the ... sequence up to 3,200 bases, ... of primers and GC clamps ... gradient gel electrophoresis (DGGE), constant ...
... RNAi Services offer you a full ... studies. B-Bridges advanced design parameters, effective ... ensure that you obtain quality results ... Design Service utilizes their proprietary B-Algo ...
Biology Products: